ACRS vs DMAC: stock comparison and AI forecast
Aclaris Therapeutics, Inc. (ACRS) and Diamedica Therapeutics Inc. (DMAC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ACRS Aclaris Therapeutics, Inc.
- Price
- $3.74 -21.3% · 6M
- Market Cap
- $551M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
DMAC Diamedica Therapeutics Inc.
- Price
- $10.00 +60.0% · 6M
- Market Cap
- $539M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ACRS and DMAC have similar market capitalizations ($551M and $539M).
- Over the last six months DMAC returned +60.0% and ACRS -21.3%.
- ACRS carries 0.44 times debt per unit of equity, against 0.17 times for DMAC.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ACRS | DMAC |
|---|---|---|
| Market Cap | $551M | $539M |
| P/B Ratio | 4.42x | 14.07x |
| EPS | $-0.55 | – |
| Book Value/Share | $0.85 | $0.71 |
| Revenue/Share | $0.06 | – |
| FCF/Share | $-0.42 | $-0.58 |
Profitability & Margins
| Metric | ACRS | DMAC |
|---|---|---|
| ROE | -60.8% | -97.9% |
| ROA | -42.1% | -83.4% |
| ROIC | -57.0% | -102.1% |
| Gross Margin | 79.5% | – |
| Operating Margin | -1050.2% | – |
| Net Margin | -921.5% | – |
| EBT Margin | -983.6% | – |
| Tax Rate | – | -0.1% |
Financial Health
| Metric | ACRS | DMAC |
|---|---|---|
| Current Ratio | 3.46x | 6.72x |
| D/E Ratio | 0.44x | 0.17x |
| Financial Leverage | 1.44x | 1.17x |
| Interest Coverage | -665.0x | -2134.0x |
| Working Capital | $70M | $38M |
Cash Flow
| Metric | ACRS | DMAC |
|---|---|---|
| Operating Cash Flow | -$62M | -$32M |
| Free Cash Flow | -$62M | -$32M |
| Capital Spending | -$120K | -$30K |
| FCF/Sales | -756.5% | – |
| CapEx/Sales | 1.4% | – |
Operational Efficiency
| Metric | ACRS | DMAC |
|---|---|---|
| Asset Turnover | 0.05x | – |
| Fixed Assets Turnover | 12.4x | – |
| Payables Period | 3365 days | – |
Income Statement
| Metric | ACRS | DMAC |
|---|---|---|
| Total Revenue | $8M | – |
| Operating Income | -$86M | -$39M |
| Net Income | -$76M | -$38M |
| R&D Expense | $63M | $29M |
| Cost of Goods Sold | $2M | – |
Dividend & Shareholder Information
| Metric | ACRS | DMAC |
|---|---|---|
| Shares Outstanding | 147M | 54M |
ACRS vs DMAC: stock comparison and AI forecast
Which is bigger, ACRS or DMAC?
ACRS and DMAC have similar market capitalizations ($551M and $539M).
Which stock performed better over the last six months, ACRS or DMAC?
Over the last six months DMAC returned +60.0% and ACRS -21.3%.
Which one does Intratio's AI model rank higher, ACRS or DMAC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.